Cu-64-LLP2A

N/A

Report date: 2025/11/20 11:38:28
NME

Base Information

Drug NameCu-64-LLP2A
Drug Alias NameCu-64-LLP2A64Cu-LLP2A
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionPositron-emission tomography enhancersIntegrin alpha-V/beta-1 modulators
TargetsIntegrin alpha-V/beta-1
Therapy Area/IndicationsAnemia, Sickle CellWaldenstrom MacroglobulinemiaMultiple Myeloma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pittsburgh
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineUniversity Of PittsburghNational Heart, Lung, And Blood Institute (Nhlbi)
Inactive CompaniesN/A
Active IndicationsAnemia, Sickle CellWaldenstrom MacroglobulinemiaMultiple Myeloma +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A